Lenvatinib Mesylate Intermediate CAS 15568-85-1 daahirnimo>97.0% (HPLC) Warshada

Sharaxaad Gaaban:

5-(Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dion

CAS: 15568-85-1

Daahirsanaanta:>97.0% (HPLC)

Muuqashada: Budada jaalaha ah

Dhexdhexaadiyaha Lenvatinib Mesylate CAS 857890-39-2

Xiriirka: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Faahfaahinta Alaabta

Alaabooyinka La Xiriira

Tags Product

Sharaxaad:

Guryaha Kiimikada:

Magaca Kiimikada 5-(Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dion
La mid ah 5-(Methoxymethylene) Asiidhka Meldrum;Cabozantinib wasakhnimo 56;Lenvatinib wasakh 79
Lambarka CAS 15568-85-1
Lambarka CAT RF-PI1967
Heerka Saamiyada Kaydka dhexdiisa, Qiyaasta Waxsoosaarka Ilaa Tan
Qaanuunka molecular C8H10O5
Miisaanka Molecular 186.16
Meesha dhalaalaysa 132.0 ~ 134.0 ℃
Cufnaanta 1.297± 0.06 g/cm3
Summada Kiimikada Ruifu

Tilmaamaha:

Shayga Tilmaamaha
Muuqashada Budada jaalaha ah
1 H NMR Spectrum Waafaqsan Qaab-dhismeedka
Daahirnimada / Habka Falanqaynta
> 97.0% (HPLC)
Wadarta wasakhda <3.00%
Heerka Imtixaanka Heerka Ganacsiga
Isticmaalka Dhexdhexaadiyaha Lenvatinib Mesylate (CAS: 857890-39-2)

Xidhmada & Kaydinta:

Xidhmada: Dhalo, bacda bireed aluminium, 25kg / Durbaan kartoonada, ama sida waafaqsan shuruudaha macmiilka

Xaaladda Kaydinta:Ku kaydi weelasha xiran meel qabow oo qallalan;Ka ilaali iftiinka iyo qoyaanka

Faa'iidooyinka

1

FAQ:

Codsiga:

5-(Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dione (CAS: 15568-85-1) waa dhexdhexaad ah Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib waa dawada kansarka qanjirka tayroodhka oo ay soo saartay Eisai Corporation of Japan (Code: E7080), oo iska leh xannibaadaha tyrosine kinase ee afka laga qaato (RTK) waxayna joojin kartaa dhaqdhaqaaqa kinase ee xuubka kobaca endothelial vascular VEGFR1 (VEGF). FLT1), VEGFR2 (KDR), iyo VEGFR3 (FLT4).Lenvatinib waxa kale oo uu joojin karaa ku lug lahaanshaha RTK-yada kale ee angiogenesis-ka pathological, koritaanka burooyinka, iyo horumarka kansarka marka laga reebo hawlahooda gacanta ee caadiga ah oo ay ku jiraan fayraska koritaanka fibroblast (FGF) receptors FGFR1, 2, 3, iyo 4;Soo-dhoweeyaha korriinka ee platelet-derived (PDGFR [alpha]), KIT, iyo RET.[Tilmaanta]: Lenvatinib waxay ku habboon tahay daaweynta bukaannada kansarka tayroodh ee soo noqnoqda deegaanka ama nooca metastasis, nooca horumarka iyo shucaaca iodine-refractory nooc kala duwan.Febraayo 13, 2015, US FDA waxay ansixisay dawada ka hortagga kansarka ee Lenvatinib si loogu daweeyo kansarka tayroodhka.Lenvatinib waa inhibitor-bartilmaameedka enzyme-ka badan, isagoo awood u leh inuu xakameeyo VEGFR2 iyo VEGFR3 (receptor endothelial factor factor receptor).Magaca ganacsiga ee Lenvatinib waa Lenvima.Maajo 20, 2015, Hay'adda Daawooyinka Yurub (EMA) ayaa u ogolaatay Lenvatinib daawaynta caabuqa, gudaha hore u maray ama kala-duwanaanta metastatic (papillary, follicular, nooca Hurthle) kansarka tayroodhka (DTC).Tijaabada dhexdeeda, wakhtiga badbaadada dhexdhexaadka ah ee bukaanada DTC shucaaca iodine-refractory ee lagu daweeyay Lenvatinib waxay ahayd 18 bilood halka qiimaha bukaanada qaata placebo ay tahay 3 bilood oo keliya.

Halkan ku qor fariintaada oo noo soo dir